NCT01363817View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 28, 2011

Primary Completion Date

February 7, 2018

Study Completion Date

February 7, 2018

Conditions
Lymphoblastic Leukemia, Acute T-cellPrecursor T-Cell Lymphoblastic Lymphoma
Interventions
DRUG

BMS-906024

DRUG

Dexamethasone

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

13273

Local Institution, Marseille

60590

Johann Wolfgang Goethe Universitaet, Frankfurt am Main

75475

Local Institution, Paris

02215

Dana Farber Cancer Institute, Boston

77030-4009

The University Of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01363817 - Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Biotech Hunter | Biotech Hunter